– Partnership leverages Scipher Medicine’s proprietary patient clinico-genomic data – In silico patient models enable pharmaceutical companies to understand what disease treatments work for which patients and why SOMERVILLE, Mass. & WALTHAM,...
Scipher to use proprietary patient molecular data analyzed by its SpectraTM platform to identify novel drug targets TARA Biosystems to progress selected targets in its BiowireTM II drug discovery platform forcardiac laminopathies. Partnership set to reduce target...
Alex Jones, Sarah Rapisardo, Lixia Zhang, Theodore Mellors, Johanna B. Withers, Zoran Gatalica, and Viatcheslav R. Akmaev Abstract: Objectives: This study reports analytical and clinical validation of a molecular signature response classifier (MSRC) that identifies...
October 12, 2021, Atlanta, GA and Waltham, MA – Trellis Rx, a leading technology-enabled specialty pharmacy services provider, today announced the integration of PrismRA, a diagnostic blood test created by Scipher Medicine that predicts non-response to TNF...
Ghiassian, Susan PhD; Withers, Johanna PhD; Akmaev, Viatcheslav PhD The American Journal of Gastroenterology: October 2021 – Volume 116 – Issue – p S431-S432 Abstract: Introduction: The map of human disease biology called the human interactome (HI)...
SEPTEMBER 24, WALTHAM, MA – Scipher Medicine, a precision immunology company matching patients with their most effective therapies, today announces the appointment of Sam A. Davis, JD, as General Counsel. Sam will lead all legal matters, including strategic...
SEPTEMBER 16, 2021 – WALTHAM, MA Scipher Medicine, a precision immunology company matching patients with their most effective therapy, today announced a partnership with Ventegra, Inc., a new class-of-trade Medical Benefits Manager that uses innovative...
Blog 07 via RxSense Specialty drug spending contributes the largest share to rising healthcare costs. To make matters worse, in the case of rheumatoid arthritis, most patients will, over time, become refractory to these specialty biologics. In some cases,...
Richard Mark Kirkner via Medscape A blood test that uses a patient’s unique genetic signature has shown some ability to predict nonresponse to tumor necrosis factor inhibitors as treatment for rheumatoid arthritis, an observational clinical study has found, but...
Blog 06 Q&A with Erin Connolly-Strong PhD, Head Medical Affairs Scipher Medicine via BiopharmaDive Multiple classes of drugs exist for treating rheumatoid arthritis (RA) patients. But close to 90% of patients failing methotrexate are prescribed the world’s largest...
Expanded intended use for the blood test validated in Network-004 study.Now, most rheumatoid arthritis patients can be tested at any point in their clinical journey.Test enables providers to identify optimal rheumatoid arthritis treatment for more than 600,000...
Blog 4 Researchers at Scipher Medicine have combined proprietary data and artificial intelligence to predict a patient’s response to costly biologics. Slava Akmaev, Ph.D., Scipher Chief Technology Officer and Head of Therapeutics describes the implications of their...
Blood Test Predicts TNFi Response in Patients Both Naïve to and Experienced with TherapyProviders Can Access Patient-Specific Data for Optimized Therapy Selection JUNE 24, 2021 – WALTHAM, MA – Scipher Medicine, a precision immunology company matching...
Molecular signature test predicts likelihood of non-response to adalimumab or etanercept, two of the world’s most expensive medications, in an independent validation cohortPrismRA demonstrates a more efficient therapy selection protocol beyond current standardThree...